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serostatus in young people in England: a
cross-sectional study
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Abstract
Background: Human cytomegalovirus (CMV) is a common herpesvirus which is estimated to infect 83% of the
global population. Whilst many infections are asymptomatic, it is an important cause of morbidity and mortality,
particularly for immunocompromised people and for infants who are congenitally infected. A vaccine against CMV
has been stated as a public health priority, but there are gaps in our understanding of CMV epidemiology. To guide
potential future vaccination strategies, our aim was to examine risk factors for CMV seropositivity in young people
in England.
Methods: The Health Survey for England (HSE) is an annual, cross-sectional representative survey of households in
England during which data are collected through questionnaires, and blood samples are taken. We randomly
selected individuals who participated in the HSE 2002, aiming for 25 participants of each sex in each single year
age group from 11 to 24 years. Stored samples were tested for CMV antibodies. We undertook descriptive and
regression analyses of CMV seroprevalence and risk factors for infection.
Results: Demographic data and serostatus were available for 732 individuals, of whom 175 (23.7%) were CMV-
seropositive. CMV seroprevalence was associated with age, with 18.3% seropositive at 11–14 years compared to
28.3% at 22–24 years. CMV serostatus was also higher in people of non-white ethnicity (adjusted odds ratio [aOR]
6.22, 95% confidence interval [CI] 3.47–11.14), and in adults who were seropositive for EBV (aOR 2.08 [1.06–4.09]).
There was no evidence that smoking status, occupation, body mass index and region of England were associated
with CMV serostatus.
Conclusions: CMV seroprevalence is strongly associated with ethnicity, and modestly increases with age in 11–24-
year-olds. A greater understanding of the transmission dynamics of CMV, and the impact of this on CMV-associated
morbidity and mortality, is necessary to inform effective vaccination strategies when a vaccine for CMV becomes
available.
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Background
The human cytomegalovirus (CMV) is a common human
herpesvirus causing lifelong infections, and is estimated to
infect 83% of the global population [1]. CMV can be trans-
mitted from symptomatic individuals, via saliva or other
body fluids and blood products [2]. Infection with CMV is
typically subclinical in healthy individuals [3], however it
is linked to multiple causes of morbidity and mortality.
CMV accounts for around 5–8% of infectious mononucle-
osis cases [4, 5], and causes disease in immunocomprom-
ised people such as transplant and cancer patients [3].
Congenitally infected newborns can suffer from cytomeg-
alic inclusion syndrome which can cause long-term
neurological damage and, in some cases, life-threatening
organ dysfunction [5].
CMV infection has been associated with shortened life
expectancy, particularly in critically ill populations and
immunocompromised people (such as those who have
undergone organ transplants) [6]. In immunocompetent
people in the UK, Gkrania-Klotsas et al. also found that
CMV seropositivity was associated with lower life
expectancy [6]. This confirmed the association reported
in a population-based cohort study from the US [7], as
well as populations in older patients [8] and those with
cardiovascular disease [9]. The association found in
Gkrania-Klotsas et al. was specifically with deaths from
causes other than cardiovascular disease and cancer,
although high levels of CMV IgG antibodies were also
associated with cardiovascular mortality [6]. Other stud-
ies in the United States, Finland and United Kingdom
found that, in immunocompetent individuals, CMV
infection and higher levels of CMV IgG antibodies were
linked to higher rates of both cardiovascular [9] and all-
cause mortality [7], as well as to cancer incidence [10]
and ischemic heart disease [11]. However, CMV is nega-
tively associated with multiple sclerosis onset [12].
In terms of biological pathways, it has been hypothe-
sised that frequent silent reactivations of CMV infection
lead to chronic inflammation, which may be a causal fac-
tor in the increased risk of mortality [6]. Additionally,
CMV seropositivity has been linked to telomere shorten-
ing of T cells, suggesting that CMV may be implicated
in immunosenescence, thereby shortening life expect-
ancy [2, 13]. There is also evidence for an immuno-
logical phenomenon called ‘memory inflation’, where a
high proportion of CD8+ T cells in older CMV-positive
individuals react to an epitope from a CMV protein [14].
This may limit the ability of the immune system to
respond to other infections and could be associated with
CMV’s ability to infect the vascular endothelium. CMV
infection also drives large expansions of cytotoxic virus-
specific CD4+ T cells in older individuals, which could
‘take up room’ in the immune system and potentially
limit responses to other pathogens [15].
Given the implications of CMV infection, anti-CMV
vaccines have been designated high priority by national
health agencies, but to date no effective vaccines appear
to be imminent [16, 17]. Mathematical modelling of the
impact of different vaccination strategies can be used to
guide vaccine development efforts and will be necessary
to inform the optimal strategies for deployment of such
a vaccine if or when it becomes available. A thorough
understanding of CMV epidemiology is necessary for the
development of such models.
CMV seroprevalence increases with age, and infection
occurs at younger ages in economically developing coun-
tries [2, 6], possibly due to higher rates of breastfeeding
than in the UK (CMV is known to be transmitted
through breast milk). A large population-based UK
cohort study found that CMV infection was more com-
mon in women than in men [6]. Lower income and edu-
cation levels, and ethnicities other than white, have been
associated with earlier age at CMV infection [18]. CMV
infection is also correlated with EBV infection [19, 20].
Socioeconomic status is strongly correlated with CMV
infection; the reasons for this could include larger family
size [21], or have been hypothesised to be a result of
stress induced by low socioeconomic status contributing
to the down-regulation of the immune system and
increased susceptibility to infection [18].
To date in the UK, studies of CMV seroprevalence
have focused on older adults [6], pregnant women [22],
and young children [23, 24]. However transmission can
occur at all ages, and the association of CMV with infec-
tious mononucleosis suggests that infection during ado-
lescence could also be an important cause of morbidity.
Therefore, our aim was to investigate the sociodemo-
graphic and lifestyle factors, particularly age, associated
with CMV serostatus in children and young adults in
England, in order to gain a better understanding of the
epidemiology of CMV in this age group.
Methods
Study population
The Health Survey for England (HSE) is a cross-
sectional annual representative survey of English house-
holds. The methods have been described previously [25].
As part of a larger study investigating Epstein-Barr virus
infection and transmission [20, 26], we used data from
randomly selected participants in the 2002 HSE, aiming
for 25 male and 25 female participants in each single-
year age group from 11 to 24 years.
Outcome: Seropositivity for Cytomegalovirus infection
We used stored blood serum samples collected by the
HSE. Commercial ELISA kits from EUROIMMUN,
Germany (EI2791–9601-G, EI2570-9601G) were used
to detect CMV-specific IgG and EBV viral capsid
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antigen (VCA)-specific IgG from the serum samples.
Assays were conducted according to the manufac-
turer’s instructions, and we calculated serum antibody
concentrations using a standard curve. Results were
presented in relative units (RU/mL) using the follow-
ing thresholds; samples of <16RU/mL were classed as
negative, ≤16 to <22RU/mL were borderline, and ≥
22RU/mL were positive. For the analyses presented
here, borderline results (CMV n = 1, EBV n = 5) were
considered seropositive [20].
Statistical analysis
We used Stata version 15.0 for data analysis. Stata’s svy
commands were used to weight our sample to be repre-
sentative of the age and sex of the 2002 English popula-
tion, using data from the Office for National Statistics
[27]. All stated percentages are weighted. We conducted
descriptive analyses of the study population. We used
ArcMap 10.3.1 to map CMV seroprevalence by English
Government Office Region [28].
We used logistic regression models to investigate fac-
tors associated with being seropositive for CMV. We
used a causal inference framework to identify a priori
factors that needed to be included in multivariable
models, drawing on the available data from the HSE.
This resulted in two multivariable regression models.
We built a ‘whole-population’ model, which included
our entire study population, to examine the following
factors: age, sex, ethnicity (categorised as ‘white’ or
‘other’ due to small numbers of non-white participants),
body mass index (BMI; categorised as ‘underweight’
[BMI < 20], ‘healthy weight’ [20–25], ‘overweight’ [25–
30] or ‘obese’ [> 30]), region of England, and EBV seros-
tatus. Additionally, we built a second ‘adults-only’ model,
which only included participants aged ≥16 years, and
additionally included data from questions which were
only asked of adults; smoking status (never smoked,
current smoker, smoked in past) and occupational cat-
egory (higher managerial and professional, intermediate
occupations, routine and manual occupations, never
worked or long-term unemployed, and other). Individ-
uals missing data on one or more variables were ex-
cluded from the regression modelling.
Ethical approval
This study was approved by the University College
London Research Ethics Committee (5683/002). The
HSE obtained informed written consent from partici-
pants at the time of recruitment for blood samples to be
collected and stored for future analyses. [15] A parent/
guardian of participants also provided written consent
for the interviewing of participants who were younger
than 16 years, and for the taking of blood samples from
participants who were younger than 18 years.
Results
Our study sample included 732 individuals aged 11–24
years, of whom 175 (23.7%) were CMV-seropositive.
Seroprevalence by participant characteristics are shown
in Table 1. There was a slight increase in CMV seroposi-
tivity associated with age, from 18.3% at 11–14 years to
28.3% at 22–24 years. CMV seroprevalence was much
lower in white people (19.2%) than people of other eth-
nicities (61.6%). Considerable variation in CMV sero-
prevalence was observed by region of England (Fig. 1,
Table 1), being highest in London (47.9%) and otherwise
varying between 16.7% in the south-east and 28.7% in
the east of England. CMV serostatus was also higher in
women (26.9%) than in men (20.4%) and people who
were EBV-seropositive (25.7%) than EBV-seronegative
(17.9%).
Univariable and multivariable regression models were
built examining the factors associated with CMV positiv-
ity. Factors associated with CMV seropositivity were
largely consistent between the univariable and multivari-
able models (Table 2), although confidence intervals
tended to be wider in the multivariable models. Ethnici-
ties other than white were strongly associated with CMV
seropositivity in both univariable and multivariable
models (adjusted odds ratio [aOR] 6.22, 95% confidence
interval [CI] 3.47–11.14). EBV serostatus was associated
with CMV serostatus in the univariable model (odds
ratio [OR] 1.59 [1.06–2.39] and in the adults-only multi-
variable model (aOR 2.08 [1.06–4.09]), but not in the
multivariable model which included children (aOR 1.21
[0.76–1.92]). Female sex was associated with higher
CMV positivity in the univariable model (OR 1.44, 1.02–
2.02); the multivariable models had similar point
estimates, but the confidence intervals included unity.
Region of England was not associated with CMV seros-
tatus in multivariable models. Neither smoking status
nor occupation were associated with CMV serostatus in
adults.
Our study sample included 732 individuals aged 11–
24 years, of whom 175 (23.7%) were CMV-seropositive.
The characteristics of seropositive individuals are shown
in Table 1. Univariable and multivariable regression
models were built examining the factors associated with
CMV positivity. Factors associated with CMV seroposi-
tivity were largely consistent between the univariable
and multivariable models (Table 2), although confidence
intervals tended to be wider in the multivariable models.
There was an increase in CMV seropositivity associ-
ated with age, from 18.3% at 11–14 years to 28.3% at
22–24 years, but the confidence intervals between strata
overlapped in logistic regression models. CMV sero-
prevalence was much higher in people of non-white eth-
nicities than in white people (61.6% vs 19.2%; aOR 6.22,
95% CI 3.47–11.14). CMV serostatus was also higher in
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Table 1 The baseline characteristics of the study population and number and weighted percentage of individuals seropositive for
CMV in England in 2002
Variable Total number Number CMV seropositive (weighted %)
Total 732 175 (23.7)
Sex
Male 364 74 (20.4)
Female 368 101 (26.9)
Age at last birthday (years)
11–14 208 39 (18.3)
15–18 212 52 (24.6)
19–21 156 40 (25.6)
22–24 156 44 (28.3)
Ethnicity
White 665 127 (19.2)
Other 77 48 (61.6)
BMI
Underweight 60 17 (28.1)
Healthy weight 418 94 (22.0)
Overweight 141 34 (23.8)
Obese 87 25 (29.9)
Missing 26 5 (19.4)
EBV serostatus
EBV-seronegative 547 34 (17.9)
EBV-seropositive 185 141 (25.7)
Region of England
East of England 78 24 (28.7)
North East 34 6 (18.0)
North West 130 27 (19.7)
Yorkshire and The Humber 82 18 (22.1)
East Midlands 74 13 (17.0)
West Midlands 70 16 (23.4)
London 63 30 (47.9)
South East 119 20 (16.7)
South West 82 21 (26.4)
Smoking statusa
Never smoked 86 52 (27.9)
Current smoker 134 35 (26.0)
smoker 147 36 (24.5)
Missing 5 3 (60.0)
Occupational categorya
Higher managerial and professional 83 26 (31.6)
Intermediate occupations 69 20 (28.9)
Routine and manual occupations 254 61 (24.0)
Never worked or long-term unemployed 11 2 (18.1)
Other 55 17 (30.3)
aAdults aged ≥16 years only (n = 472). Percentages account for the weighting of the sample to be representative of the English population in 2002 with respect to
age and sex. BMI body mass index, CI confidence interval, CMV cytomegalovirus, EBV Epstein-Barr virus
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women (26.9%) than in men (20.4%); the CI for this
association excluded unity in a univariable model (odds
ratio [OR] 1.44, 95% confidence interval [CI] 1.02–2.02);
the multivariable models had similar point estimates, but
the confidence intervals included unity. Neither smoking
status nor occupation were associated with CMV seros-
tatus in adults.
CMV seropositivity was higher in people who were
EBV-seropositive (25.7%) than EBV-seronegative (17.9%).
EBV serostatus was associated with CMV serostatus in the
univariable model (OR 1.59 [1.06–2.39] and in the adults-
only model (aOR 2.08 [1.06–4.09]), but not in the multi-
variable model which included children (aOR 1.21 [0.76–
1.92]).
Considerable variation in CMV seroprevalence was
observed by region of England (Fig. 1, Table 1), CMV
seroprevalence was highest in London (47.9%) and
otherwise varied between 16.7% in the south-east to
Fig. 1 Weighted Cytomegalovirus seroprevalence by English Government Office Region in 2002. Contains National Statistics data©. Crown
copyright and database right [2011]. Contains public sector 6 information licensed under the Open Government Licence v3.0
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Table 2 Univariable and multivariable logistic regression models of factors associated with Cytomegalovirus seropositivity in
England in 2002
Whole-population Adults onlya
Univariable OR (95% CI) Multivariable aOR (95% CI) Multivariable aOR (95% CI)
Sex
Male 1.00 1.00 1.00
Female 1.44 (1.02–2.02) 1.39 (0.95–2.05) 1.50 (0.95–2.35)
Age at last birthday (years)
11–14 1.00 1.00
15–18† 1.46 (0.89–2.40) 1.55 (0.88–2.75) 1.00
19–21 1.54 (0.89–2.66) 2.24 (1.21–4.14) 1.05 (0.58–1.91)
22–24 1.76 (1.04–2.99) 1.77 (0.95–3.29) 0.74 (0.38–1.46)
Ethnicity
White 1.00 1.00 1.00
Other 6.75 (4.23–10.77) 6.22 (3.47–11.14) 6.98 (3.18–15.32)
BMI
Underweight 1.39 (0.77–2.52) 1.18 (0.62–2.24) 0.98 (0.50–1.93)
Healthy weight 1.00 1.00 1.00
Overweight 1.11 (0.71–1.74) 1.15 (0.71–1.86) 0.84 (0.47–1.53)
Obese 1.52 (0.90–2.56) 1.50 (0.81–2.77) 1.06 (0.40–2.76)
EBV serostatus
Negative 1.00 1.00 1.00
Positive 1.59 (1.06–2.39) 1.21 (0.76–1.92) 2.08 (1.06–4.09)
Region of England
East of England 1.00 1.00 1.00
North East 0.54 (0.18–1.66) 0.51 (0.17–1.50) 0.57 (0.16–2.02)
North West 0.61 (0.31–1.19) 0.62 (0.31–1.22) 0.60 (0.25–1.40)
Yorkshire and The Humber 0.70 (0.33–1.51) 0.67 (0.30–1.51) 0.62 (0.26–1.47)
East Midlands 0.51 (0.21–1.19) 0.52 (0.21–1.26) 0.70 (0.24–2.04)
West Midlands 0.76 (0.35–1.63) 0.81 (0.36–1.79) 0.53 (0.18–1.60)
London 2.28 (1.13–4.61) 1.18 (0.52–2.69) 1.28 (0.45–3.61)
South East 0.50 (0.24–1.03) 0.43 (0.20–0.93) 0.44 (0.17–1.14)
South West 0.89 (0.46–1.70) 1.09 (0.55–2.15) 0.72 (0.29–1.78)
Smoking statusa
Never smoked 1.00 – 1.00
Current smoker 0.91 (0.54–1.51) – 1.08 (0.58–2.01)
Smoked in past 0.84 (0.51–1.38) – 0.96 (0.54–1.69)
Occupational categorya
Higher managerial and professional 1.00 – 1.00
Intermediate occupations 0.88 (0.44–1.76) – 0.66 (0.31–1.42)
Routine and manual occupations 0.68 (0.40–1.18) – 0.63 (0.32–1.24)
Never worked or long-term unemployed 0.48 (0.09–2.45) – 0.40 (0.07–2.14)
Other 0.94 (0.46–1.93) 0.47 (0.17–1.28)
aAdults aged ≥16 years only (n = 472). †16–18 years for ‘adult-only’ model. Odds ratios account for the weighting of the sample to be representative of the English
population in 2002 with respect to age and sex. The ‘whole population’ multivariable model included age, sex, CMV serostatus, ethnicity, BMI and region of
England. The ‘adults only’ multivariable model included all variables shown in the table. aOR adjusted odds ratio, BMI body mass index, CI confidence interval,
CMV cytomegalovirus, OR unadjusted odds ratio
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28.7% in the east of England. However, region of
England was not associated with CMV serostatus in
multivariable models.
Discussion
In this study of young people in England, we found that
just under a quarter of people aged 11–24 years were
infected with CMV, and that seroprevalence increased
over this age range. CMV infection was also strongly
correlated with non-white ethnicity and more weakly
associated with EBV infection. There was no association
observed between CMV and region of England, smoking
status, BMI, or occupation.
CMV and EBV serostatus were positively associated in
univariable analyses, and when the multivariable analysis
was restricted to adults, but not in the multivariable
model which also included children aged 11–15 years.
As discussed in our previous paper [20], both CMV and
EBV are associated with increasing age, however EBV
increases more rapidly during adolescence than CMV.
Thus, in a whole-cohort model adjusting for age, this
association may not be visible. As the associations
between age and both CMV and EBV [20] are less
strong in adults, it is possible that there was enough of a
residual effect that the association between CMV and
EBV could be detected in the adults-only model. Given
the cross-sectional nature of our study, the relative
temporality of the two infections could not be
assessed. Although established, the relationship be-
tween CMV and EBV is not well understood. It is
known that EBV seroprevalence is higher than CMV
seroprevalence in all age groups and that both in-
crease with age [20], but it is not known whether
this relationship is causal or whether the association
results from shared genetic, immunological and/or
sociodemographic risk factors. Longitudinal studies
with serial testing and a larger sample size would be
necessary to explore this association in more detail.
We observed a strong association between ethnicity
and CMV seroprevalence; the odds of being CMV posi-
tive were approximately seven time higher for people of
ethnicities other than white than for white people. This
may be the result of different social mixing patterns, lar-
ger households, different eating or hygiene habits, lower
breastfeeding rates in white people (resulting in less ver-
tical transmission of CMV through breastmilk), possibly
different countries of birth (of participants or their
parents) or residual confounding of socioeconomic
status. This strong association with ethnicity is also
likely to be a confounder in the association between
CMV and region, particularly London, that was only
observed in univariable models, as there is a higher
proportion of ethnic minorities living in London than
elsewhere in England [29]. We were unable to analyse
associations with ethnicity in more detail due to small
numbers of participants; the “non-white” group com-
prised 57% Asian/Asian British (n = 44), 19% black/
black British (n = 15), 14% mixed ethnicity (n = 11)
and 9% other ethnicity (n = 7). Further study of the
association of ethnicity with CMV seroprevalence is
needed in diverse cohorts.
Our study benefits from a sample drawn from a
highly rigorous, annual, representative survey of
people in England, which we weighted to be represen-
tative of the English population, and the use of a
quality-managed commercial assay to measure the
antibody response. The limitations of our work
include the use of a cross-sectional study design, pre-
venting determination of the temporality of certain
associations, and the age of the data; 2002 was the
most recent year for which the HSE collected consent
to analyse blood samples for blood-borne viruses.
More recent data from the UK biobank found that
58% of those aged 40–69 years were seropositive for
CMV at enrolment (2006–2010) [30], and as CMV
seroprevalence increases with age throughout life, the
prevalence observed in young people in our study is
consistent with what could be expected. An older
study examined CMV seroprevalence in 1991 and
2002 and found that prevalence in young people did
not differ between these two timepoints [31], and so
there is no particular reason to believe CMV sero-
prevalence has changed substantially since then. We
also consider it unlikely that the associations between
CMV and the risk factors we studied would have
changed substantially since 2002, and therefore the
associations we observed are likely to be consistent
today even if there had been a slight change in CMV
seroprevalence.
The relatively low seroprevalence of CMV meant
this study may have lacked power to detect associa-
tions, particularly in the multivariable models. We
were also limited in the variables that were available,
we were unfortunately unable to examine associations
with household size or household income. Addition-
ally, the geographical variables available were lacking
in granularity, meaning we were not able to explore
regional differences in more depth or examine
whether regional variation was associated with other
sociodemographic risk factors.
We observed only a modest increase in CMV sero-
prevalence associated with age, suggesting that adoles-
cence is not a key transmission period for CMV as it is
for EBV (for which seroprevalence increases from 60%
in 11–14 year olds to 93% in 22–24 year olds [20]). This
may contribute to the lower incidence of CMV-
associated (versus EBV-associated) infectious mono-
nucleosis [4, 5]. Previous studies have shown that 15% of
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white British and 44% of British Pakistani infants were
infected with CMV by the age of 2 years, and that sero-
prevalence was 59% in an adult cohort aged 40–79 years.
In combination with our results, this suggests that after
early childhood, there is no ‘key’ age group in which
CMV seroprevalence sharply increases, and that infec-
tion continues to increase during adulthood, particularly
for white British individuals. A better understanding of
the interactions between age at CMV infection, and the
development of CMV-related morbidity and mortality, is
necessary to be able to develop an appropriate vaccin-
ation strategy, when a vaccine becomes available.
Conclusions
CMV seroprevalence is strongly associated with ethnicity,
and modestly increases with age. A greater understanding
of the transmission dynamics of CMV, and the impact of
this on CMV-associated morbidity and mortality, is neces-
sary to inform effective vaccination strategies when a
vaccine for CMV becomes available.
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